OZ, a global consulting company enhancing customer experiences through digital innovation, recently launched a first-of-its-kind application that brings an augmented reality (AR) environment to... read more
OZ, a global consulting company enhancing customer experiences through digital innovation, recently launched a first-of-its-kind application that brings an augmented reality (AR) environment to... read more
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, Provided the results of its first human study on 4/8/19.
The study was primarily undertaken to show... read more
Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, updated its S-1 Filing. The company is proposing... read more
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) announced on 4/5/19 that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid... read more
C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on bacteriophage, today announced that the United... read more
Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, have signed an agreement to establish a 50/50 joint venture to pioneer... read more
Just a month ago, Silk Road filed for its IPO with an expected maximum of $86 million. The company just amended the filing with a new expected maximum of $138 million. The company intends to trade... read more
Cambridge Innovation Capital plc (CIC), the venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem, has completed a... read more
Enterome SA announced on 3/27/19 that it will present data on its innovative microbiome-based approach for the development of therapeutic peptide cancer vaccines for the first time in a poster at... read more
Genome editing company, Precision BioSciences, raised $126.4 million in its IPO on Wednesday. The company sold 7.9 million shares of stock at a public offering price of $16 per share. When it... read more
Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses, announced on 3/27/19 the... read more
NGM Updated its IPO filing to include an estimated price range of $14 to $16 per share. If all available shares are purchased, the IPO will raise more than $122 Million. The company intends to... read more
Saama Technologies, Inc. (“Saama”), a leading clinical data analytics platform firm, announced on 3/25/19 that it has closed a $40 million financing with Perceptive Advisors. The new funding will... read more
Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, announced today it has filed a registration... read more
Enterome SA announced on 3/20/19 that is has entered into a research and development collaboration with Dana-Farber Cancer Institute (Boston, MA) to evaluate and develop gut microbiome-derived... read more
Flagship Pioneering announced on 3/20/19 that it has secured $824 million in a new capital pool to support the growth of human health and sustainability companies originated by its Flagship Labs... read more
